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Introduction to the session

Introduction to the questions (anything missing)
10 min
Working session groups
25 min
Report back 5 min/group
40 min
Wrap up
10 min

Timing

Logistics

Session

Each Group

Questions

1.5 hours

Each table addresses one topic

~ 72 participants

Identifies other key points

7 groups

One person per table to take notes

Batch definition
Characterization & validation
Viral clearance
PAT
Bioburden
Sampling
Systems Integration

One person per table to present

Group Topics
1.

How do you define a batch for continuous & semi-continuous processes
from a regulatory perspective?

2.

Validation of continuous processes how do we meet current regulatory
expectations?

3.

How do we meet regulatory requirements requiring us to demonstrate
viral reduction throughout the process?

4.

What PAT technologies are needed to support robust in-line monitoring?

5.

What are your in-process bioburden control strategies?

6.

How and where are samples taken in a continuous process?

7.

What are implications of system integration from a regulatory
perspective?

1. How do you define a
batch for continuous &
semi-continuous
processes from a
regulatory perspective?

• How did you/will you define a batch for continuous
processes?
• What data did you use/would you use to justify the
batch definition?
• What in-process pooling criteria did you/will you
use for processes with variable PQ day to day?
• How much PQ variability is acceptable a particular
release specification (e.g., glycosylation level,
charge heterogeneity)? What data would you have
to justify your stance?
• Are any of the above dependent on MOA (e.g.,
nuances in batch to batch consistency for a-fucose)?
• What are the implications of start up and shutdown

2. Validation of
continuous processes
how do we meet current
regulatory expectations?

• Process characterization needs to account for the
connectivity between steps. What is your approach
for DOE – partition design vs testing isolated unit
operations?
• How do you show the process is in a state of
control?
• For instance, how do you demonstrate cycle-tocycle consistency on downstream chromatography
columns that are cycled 50-200 times?
• What data would you show to justify your stance?
• Are there different strategies for Upstream
compared to Downstream

3. How do we meet
regulatory requirements
requiring us to
demonstrate viral
reduction throughout the
process?

• How do you validate continuous virus inactivation?
• How do you validate VRF in a continuous process?
• How do you demonstrate viral clearance in a
continuous chromatography column
• Do you use one membrane system continuously for
14-60 days?
• Or do you change membranes every day?
• What are the criteria to be used for changing them?

• How do you show the process is in a state of
control?
• For normal steady state, start-up and shutdown
considerations

4. What PAT technologies
are needed to support
robust in-line monitoring?

• For instance, how do you demonstrate cycle-tocycle consistency on downstream chromatography
columns that are cycled 50-200 times?
• What data would you show to justify your stance?

• Can we use PAT to adjust process perturbations in
real time steering process to a optimum?
• How do you manage process deviations?

5. What are your inprocess bioburden
control strategies?

• What are your in-process bioburden control strategies
for processes that operate continuously for 14 – 60 days
downstream?
• Do you sanitize everything daily?
• Do you rely on sterile materials and filters and forgo
sanitization?
• How do you change non active SU components (bags
tubing)

• Methods for taking a sample

6. How and where are
samples taken in a
continuous process?

• Frequency
• Device and controller delays
• Uniformity

• Start up vs. steady state

• Do we need increased understanding of the interaction
between linked unit operations?

7. What are implications of
system integration from a
regulatory perspective?

• To ensure stable operation
• Resident time distributions
• Implication for feedback/feedforward control

• Are there data management issues
• How do we deal with changes and disturbances?
• Raw materials
• Changes in process conditions (titre from the bioreactor)

Wrap Up 5 min/group
•
•
•
•

What did you discuss
Conclusions
Unresolved issues
Other points for consideration

Thank you

